Examining the effectiveness of hydroxyurea in people with sickle cell disease

Journal of Health Care for the Poor and Underserved

Volumn 21, Issue 1, 2010, Pages 277-286

  Lanzkron, Sophie ^a   Haywood Jr , Carlton ^a   Fagan, Peter J ^b   Rand, Cynthia S ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Johns Hopkins Berman Institute of Bioethics ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISICKLING AGENT; HYDROXYUREA;

ADOLESCENT; ADULT; AGED; AMBULATORY CARE; ARTICLE; DRUG UTILIZATION; ECONOMICS; EVALUATION; FEMALE; HEALTH CARE COST; HEALTH INSURANCE; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MALE; MEDICAID; MIDDLE AGED; RETROSPECTIVE STUDY; SICKLE CELL ANEMIA; STATISTICS; UNITED STATES;

ADOLESCENT; ADULT; AGED; AMBULATORY CARE; ANEMIA, SICKLE CELL; ANTISICKLING AGENTS; DRUG UTILIZATION; FEMALE; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; HYDROXYUREA; LENGTH OF STAY; MALE; MANAGED CARE PROGRAMS; MARYLAND; MEDICAID; MIDDLE AGED; RETROSPECTIVE STUDIES; UNITED STATES; YOUNG ADULT;

EID: 77249171797     PISSN: 10492089     EISSN: None     Source Type: Journal    
DOI: 10.1353/hpu.0.0272     Document Type: Article

References (12)

1. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med. 1994;330:1639-1644
2. McClish D, Penberthy L, Bovbjerg V, et al. Health related quality of life in sickle cell patients: the PiSCES project. Health and Quality of Life Outcomes. 2005;3:50.
3. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med. 1995;332:1317-1322
4. Moore RD, Charache S, Terrin ML, et al. Cost-effectiveness of hydroxyurea in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Am J Hematol. 2000;64:26-31.
5. The Management of Sickle Cell Disease. Bethesda, MD: NIH, 2002.
6. Lanzkron S, Haywood C Jr, Segal JB, et al. Hospitalization rates and costs of care of patients with sickle-cell anemia in the state of Maryland in the era of hydroxyurea. Am J Hematol. 2006;81:927-932
7. Zumberg MS, Reddy S, Boyette RL, et al. Hydroxyurea therapy for sickle cell disease in community-based practices: a survey of Florida and North Carolina hematologists/ oncologists. Am J Hematol. 2005;79:107-113
8. Lanzkron S, Haywood C, Hassell K, et al. Provider barriers to hydroxyurea use in adults with sickle cell disease: a survey of the sickle cell disease adult provider network. Journal of the National Medical Association. (In press.)
9. Frei-Jones MJ, Field JJ, Debaun MR. Multi-modal intervention and prospective implementation of standardized sickle cell pain admission orders reduces 30-day readmission rate. Pediatr Blood Cancer. 2009.
10. Ballas SK, Lusardi M. Hospital readmission for adult acute sickle cell painful episodes: frequency, etiology, and prognostic significance. Am J Hematol. 2005;79:17-25.
11. Betancourt JR, Maina AW. The Institute of Medicine Report-"Unequal treatment": implications for academic health centers. Mount Sinai Journal of Medicine. 2004;71:314-321
12. Tamayo-Sarver JH, Hinze SW, Cydulka RK, et al. Racial and ethnic disparities in emergency department analgesic prescription. Am J Public Health. 2003;93:2067-2073